



**VIJAYA**<sup>®</sup>  
**DIAGNOSTIC**  
**CENTRE**

**May 09, 2024**

To,  
Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051  
**NSE Symbol: VIJAYA**

To,  
The Corporate Relations Department  
**BSE Limited,**  
Phiroz Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street  
Mumbai- 400 001  
**BSE Scrip Code: 543350**

Dear Sir/Madam,

**Sub: Submission of Newspaper Publication(s)**

Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published the audited financial results of the Company for the fourth quarter and financial year ended March 31, 2024 in Financial Express (English) and Nava Telangana (Telugu) newspapers on Thursday, May 09, 2024. Copies of the said Newspaper publications are enclosed herewith.

Please take the information on record.

Thanking you.

**For Vijaya Diagnostic Centre Limited**

**Hansraj Singh**  
**Company Secretary & Compliance Officer**  
**M.No.F11438**

Encl.: As above

**J.G.Chemicals Limited**  
 Adventz Infinity@5, Unit No. 1511, Street No. 18, BN Block, Sector - V, Salt Lake City, Kolkata - 700 091, India, Email: corporate@jgchem.com | Web: www.jgchem.com CIN: L24100WB2001PLC093380

**Extract of the Audited Consolidated Financial Results for the Quarter and Year ended March 31, 2024** (₹ in Crores)

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	31-03-2024 (Audited)	31-12-2023 (Unaudited)	31-03-2023 (Audited)	31-03-2024 (Audited)	31-03-2023 (Audited)
Revenue from operations	181.36	161.32	194.25	667.69	784.58
Profit before exceptional item and tax	18.15	14.68	16.11	44.90	76.70
Profit before tax	18.15	14.68	16.11	43.10	76.70
Profit after tax	13.60	10.64	11.75	32.11	56.79
Total comprehensive income for the period	17.60	11.35	11.81	36.83	56.89
Paid up Equity Share Capital	39.19	31.72	31.72	39.19	31.72
Total reserves (including non-controlling interests)				366.32	181.81
Earnings per Equity Share ( of ₹10 each) - Basic and Diluted (Not Annualised *)	₹4.00	₹3.22	₹3.57	₹9.60	₹17.32

**Notes:**  
 1. Additional information on Audited Standalone Financial Results is as follows:

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended	Year ended
	31-03-2024 (Audited)	31-12-2023 (Unaudited)	31-03-2023 (Audited)	31-03-2024 (Audited)	31-03-2023 (Audited)
Revenue from operations	67.15	53.76	83.74	244.65	335.30
Profit before exceptional item and tax	6.42	5.44	5.89	16.21	34.25
Profit before tax	6.42	5.44	5.89	14.40	34.25
Profit after tax	4.87	3.81	4.30	10.79	25.22

2. The Audited Consolidated Financial Results and Audited Standalone Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 08th May, 2024. The Statutory Auditors have expressed an unmodified audit opinion on these results.

3. The above is an extract of the detailed format of Financial Results filed with Stock Exchanges under Regulation 33 of SEBI (LODR) Regulations, 2015. The full format of the standalone and consolidated Financial Results for the quarter and year ended March 31, 2024, are available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)), the National Stock Exchange of India Limited website (URL: [www.nseindia.com](http://www.nseindia.com)) and on the Company's website (URL: [www.jgchem.com](http://www.jgchem.com)).

By order of the Board  
 For J.G.Chemicals Limited  
 Sd/-  
 Anirudh Jhunjhunwala  
 Managing Director and CEO

Date: 08.05.2024  
 Place: Kolkata

**TCI FINANCE LIMITED**  
 Regd Office: Plot No 20, Survey No 12, 4th Floor, Kothaguda, Kondapur, Hyderabad - 500081. CIN: L65910TG1973PLC031293, www.tcifin.in Phone No: 040-71204284 & Fax No: 040-23112318

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2024** (₹ IN LAKHS)

PARTICULARS	QUARTER ENDED		YEAR ENDED	
	31-03-2024 Audited	31-12-2023 Unaudited	31-03-2023 Audited	31-03-2024 Audited
Total income from operations (Net)	0.07	0.02	0.02	65.09
Net Profit / (Loss) from ordinary activities after tax	(44.19)	27.12	(40.30)	(43.47)
Net Profit / (Loss) for the period after tax (after Extraordinary items)	(48.69)	27.12	(40.30)	(47.97)
Total Comprehensive Income for the period (comprising Profit (Loss) and other Comprehensive Income for the period)	(482.59)	(571.68)	(958.30)	(50.67)
Equity Share Capital	1287	1287	1287	1287
Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				(7,756)
Earnings Per Share (before extraordinary items) (₹10/- each) Earnings Per Share (before extraordinary items) (₹10/- each)				
Basic :	(0.38)	0.21	(0.31)	(0.37)
Diluted :	(0.38)	0.21	(0.31)	(0.37)
Earnings Per Share (after extraordinary items) (₹10/- each) Earnings Per Share (after extraordinary items) (₹10/- each)				
Basic :	(0.38)	0.21	(0.31)	(0.37)
Diluted :	(0.38)	0.21	(0.31)	(0.37)

**Notes:**  
 1) The above results have been reviewed by the audit committee and approved by the Board of Directors at their meeting held on May 8, 2024  
 2) The above is an extract of the detailed format of year ended March 31, 2024 Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format for the year ended March 31, 2024 are available for investors at [www.tcifin.in](http://www.tcifin.in), [www.bseindia.com](http://www.bseindia.com) & [www.nseindia.com](http://www.nseindia.com).

For and on behalf of the Board  
 Mahendra Kumar Agarwal  
 Director  
 DIN : 0179779

Place : Hyderabad  
 Date : 08-05-2024

**VIJAYA DIAGNOSTIC CENTRE LIMITED**  
 CIN: L85195TG2002PLC039075  
 Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India  
 Phone: 040-23420422, Website: [www.vijayadiagnostic.com](http://www.vijayadiagnostic.com), Email: [ir@vijayadiagnostic.in](mailto:ir@vijayadiagnostic.in)

**Extract of Audited Consolidated Financial Results for the quarter and year ended 31 March 2024** (₹s. in Lakhs except as stated)

S. No.	Particulars	3 months ended	Year ended	3 months ended
		31 Mar 2024 (Audited)	31 Mar 2024 (Audited)	31 Mar 2023 (Audited)
1	Total Income from Operations (net)	15,520.52	54,780.53	12,099.28
2	Net Profit for the period before Tax and Exceptional items #	4,386.85	16,073.09	3,650.09
3	Net Profit for the period before Tax and after Exceptional items #	4,386.85	15,868.09	3,650.09
4	Net Profit for the period after Tax and after Exceptional items #	3,367.76	11,963.71	2,772.67
5	Total comprehensive income for the period #	3,342.00	11,952.49	2,778.50
6	Paid-up equity share capital (Face value of Re. 1 each)	1,023.46	1,023.46	1,020.71
7	Other equity (excluding revaluation reserve) as per audited balance sheet of previous year	53,452.23	53,452.23	45,802.27
8	Earnings per equity share (Face value of Re. 1 each) (non annualized for quarter and year-to-date ended)			
	- Basic (in Rs.)	3.27	11.62	2.69
	- Diluted (in Rs.)	3.26	11.59	2.68

# Before Non-controlling interest

**Notes:**  
 1. Key numbers of the standalone financial results are as under:

S. No.	Particulars	3 months ended	Year ended	Corresponding
		31 Mar 2024 (Audited)	31 Mar 2024 (Audited)	31 Mar 2023 (Audited)
1	Total Income from Operations (net)	14,105.20	52,502.27	11,833.29
2	Profit for the period before tax and exceptional items	3,980.21	15,452.17	3,554.45
3	Profit for the period before tax (PBT)	3,980.21	15,247.17	3,554.45
4	Profit for the period after tax (PAT)	3,050.91	11,460.20	2,692.40
5	Total Comprehensive Income	3,023.93	11,447.76	2,697.46

2. The above financial results for the quarter and the year ended 31 March 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08 May 2024.

3. The above is an extract of the detailed format of quarterly and year ended financial results filed with the stock exchange under Regulation 33 of the SEBI LODR Regulations, 2015. The full format of the quarterly and year ended financial results are available on the stock exchange websites ([www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)) and the Company's website ([www.vijayadiagnostic.com](http://www.vijayadiagnostic.com)).

for and on behalf of the Board of Directors of  
 Vijaya Diagnostic Centre Limited  
 Sd/-  
 Sunil Chandra Kondapally  
 Executive Director  
 DIN: 01409332

Place: Hyderabad  
 Date: May 08, 2024

This is only an advertisement for information purposes and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated Monday, May 06, 2024 (the 'Letter of Offer') filed with the Stock Exchange, namely BSE Limited ('BSE'), where presently the Equity Shares of the Company are listed; and the Securities and Exchange Board of India ('SEBI')

**BANAS FINANCE LIMITED**  
 Corporate Identification Number: L65910MH1983PLC030142;  
 Registered Office: E-109, Crystal Plaza, New Link Road, Andheri (West), Mumbai - 400053, Maharashtra, India;  
 Contact Number: +91-9152096140; Contact Person: Prajna Prakash Naik, Company Secretary & Compliance Officer;  
 Email Address: banasfn@gmail.com; Website: [www.banasfinance.wordpress.com](http://www.banasfinance.wordpress.com)

**PROMOTERS OF THE COMPANY ARE GIRRAJ KISHOR AGRAWAL, TANU GIRRAJ AGRAWAL, HANDFUL INVESTRADE PRIVATE LIMITED, AND HUNNAR JEWELS LIMITED (FORMERLY KNOWN AS AGRAWAL BULLION LIMITED ISSUER).**

FOR PRIVATE CIRCULATION TO THE EQUITY SHAREHOLDERS OF OUR COMPANY (THE 'COMPANY' OR 'THE ISSUER') ONLY  
 RIGHTS ISSUE OF 4,80,46,232 (FOUR CRORES EIGHTY LAKHS FORTY SIX THOUSAND TWO HUNDRED AND THIRTY TWO) EQUITY SHARES OF FACE VALUE OF 10.00/- (RUPEES TEN ONLY) ('EQUITY SHARES') EACH AT AN ISSUE PRICE OF ₹10.00/- (RUPEES TEN ONLY) PER EQUITY SHARE ('ISSUE PRICE') ('RIGHT SHARES') FOR AN AMOUNT NOT EXCEEDING 4804.62 LAKHS (RUPEES FORTY-EIGHT CRORE FOUR LAKHS SIXTY TWO THOUSAND THREE HUNDRED AND TWENTY ONLY) ON A RIGHT ISSUE BASIS TO THE ELIGIBLE SHAREHOLDERS OF BANAS FINANCE LIMITED ('COMPANY' OR 'ISSUER') IN THE RATIO OF 1 (ONE) RIGHTS SHARES FOR EVERY 1 (ONE) EQUITY SHARES HELD BY SUCH ELIGIBLE SHAREHOLDERS AS ON THE RECORD DATE, FRIDAY, APRIL 26, 2024 ('ISSUE'). THE ISSUE PRICE AT PAR WITH THE FACE VALUE OF THE EQUITY SHARE. FOR FURTHER DETAILS, KINDLY REFER TO THE SECTION TITLED 'TERMS OF THE ISSUE' BEGINNING ON PAGE 143 OF THE LETTER OF OFFER

**NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY**

<b>ISSUE OPENS ON:</b> MONDAY, MAY 13, 2024	<b>LAST DATE FOR ON MARKET RENUNCIATION*</b> FRIDAY, 17 MAY, 2024	<b>ISSUE CLOSURES ON**</b> THURSDAY, 30 MAY, 2024
--	--	--

\*Eligible Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renounee on or prior to the Issue Closing Date.  
 \*\* Our Board or a duly authorized committee thereof will have the right to extend the Issue Period as it may determine from time to time, provided that this issue will not remain open in excess of 30 (thirty) days from the Issue Opening Date. Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

<b>ASBA*</b>	Simple, Safe, Smart way of making an application- Make use of it!!!	*Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check selection on ASBA below.
--------------	---	---

Application in this issue shall be made using the ASBA Facility in accordance with Regulation 76 of the SEBI (ICDR) Regulations, the SEBI Right Issue Circulars and the ASBA Circulars, all Investors desiring to make an Application in this issue are mandatorily required to use the ASBA process only. Investors should carefully read the provisions applicable to such Applications before making their Application through ASBA.

Please note that subject to the SCSBs Complying with the requirement of the SEBI circular bearing reference number CIR/CFD/DIL/13/2012 dated September 25, 2012. Within the periods stipulated therein, Applications may be submitted at the Designated Branches of the SCSBs. Further, in terms of the SEBI circular bearing reference number CIR/CFD/DIL/1/2013 dated January 02, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI registered SSB(s). Such Account shall be used solely for the purpose making an application in this issue and clear demarcated funds should be available in such account for such an Application.

Pursuant to the provisions of the SEBI ICDR Regulations and the SEBI Rights Issue Circulars and in terms of the Letter of Offer, the Rights Entitlements of the Eligible Equity Shareholders have been credited in their respective demat account and shall be admitted for trading on the Stock Exchange under the ISIN - 'INE521L20022' subject to requisite approvals. For details of credit of the Rights Entitlement, see 'Terms of the Issue - Credits of Right Entitlements in demat accounts of Eligible Equity Shareholders' on page 143 of the Letter of Offer.

In accordance with the Regulation 77A of the SEBI (ICDR) Regulations read with the SEBI Rights Issue circulars the credit of Rights Entitlement and Allotment of rights equity shares shall be made in dematerialized only.

Eligible Equity Shareholders, whose Rights Entitlements are credited in demat suspense escrow account opened by our Company, are requested to provide relevant details (such as copies of self-attested PAN and client master sheet of the demat account etc., details/ records confirming the legal and beneficial ownership of their respective Equity Shares) to the Company or the Registrar not later than Tuesday, May 28, 2024, being 2(Two) Working Days prior to the Issue Closing Date being Thursday, May 30, 2024, to enable the credit of the Rights Entitlements by way of transfer from the demat suspense escrow account to their respective demat accounts on Wednesday 29 May, 2024, being at least 1 (One) day before the Issue Closing Date being Thursday, May 30, 2024, to enable such Eligible Equity Shareholders are also requested to ensure that the demat account is active, details of which have been provided to the Company or the Registrar to facilitate the aforementioned transfer. Eligible Equity Shareholders holding Equity Shares in physical form can update the details of their demat account on the website of the Registrar [www.purvashare.com](http://www.purvashare.com); Such Eligible Equity Shareholders can make an application only after the Rights Entitlement is credited to the respective demat accounts.

**PLEASE NOTE THAT CREDIT OF THE RIGHTS ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE THE INVESTORS TO THE RIGHTS EQUITY SHARES AND THE INVESTORS HAVE TO SUBMIT APPLICATION FOR THE RIGHTS EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE AND MAKE PAYMENT OF THE APPLICATION MONEY. FOR DETAILS, PLEASE SEE THE SECTION ENTITLED 'TERMS OF THE ISSUE - PROCESS OF MAKING AN APPLICATION IN THE ISSUE ON PAGE 143 OF THE LETTER OF OFFER.**

**APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA):** An Investor wishing to participate in this issue through the ASBA facility is required to have an ASBA enabled bank account with SCSBs, prior to making the Application. Investors desiring to make an Application in this issue through ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/electronic Application through the website of the SCSBs (if made available by such SCSB) for Authorizing such SCSB to block application Money payable on the application in their respective ASBA Accounts. For the list of the banks which have been notified by SEBI to act as SCSBs for the ASBA process, please refer to the 156. For details on Designated Branches of SCSBs collecting the Application Form, please refer above mentioned links.

**ELIGIBLE EQUITY SHAREHOLDERS UNDER THE ASBA PROCESS MAY PLEASE NOTE THAT THE EQUITY SHARES UNDER THE ASBA PROCESS CAN BE ALLOTTED ONLY IN DEMATERIALIZED FORM AND TO THE SAME DEPOSITORY ACCOUNT IN WHICH THE EQUITY SHARES ARE HELD BY SUCH ASBA APPLICANT ON THE RECORD DATE.**

**APPLICATION ON PLAIN PAPER:**  
 An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this issue on plain paper in case of non-receipt of the Application Form as detail above. In such cases of non-receipt of the Application form, through the physical delivery (where applicable) and all eligible Equity shareholders not being in a position to obtain it from any other source may make an application to subscribe to this issue on the plain paper with the same details as per Application form that is available on the website of the Registrar, Stock Exchange or the Lead manager. An eligible Equity shareholder shall submit the plain application paper to the designated branch of the SCSBs to the block application money in the said bank account maintained with the same SCSB. Applications on the plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that Eligible Equity Shareholders who are making an applications on the plain paper shall not be entitled to renounce their Rights Entitlement and should not utilize the Application form for any purpose including renunciation even if it is received subsequently.

The Application on the plain paper duly signed by the Eligible Equity Shareholder including joint holders, in the same order and as per the specimen recorded with per him/her bank, must reach the office of the Designated Branch of the SCSBs before Issue Closing Date being Thursday, May 30, 2024, and should contain following particulars:

- Name of our Company, being Banas Finance Limited;
- Name and Addressee of the Equity shareholders including joint holders (in the same order and as per specimens recorded with our company or the depository);
- Folio Number (in case of Eligible Equity Shareholders who hold Equity shareholding in physical form as on the Record Date) DP and Client ID;
- Except for the application on the behalf of the central and state government, the residents of Sikkim and the officials appointed by courts, PAN of the Eligible Equity shareholder and for each Eligible Equity shareholders in case of joint ventures, irrespective of the total value total value of Equity shares applied for pursuant to this issue;
- Number of Equity shareholders as per Record Date;
- Allotment option - (only Dematerialised form);
- Number of Equity shares entitled to;
- Number of rights Equity shares applied for within rights entitlement;
- Number of additional right Equity shares applied for, if any (applicable only if entire rights entitlement have been applied for);
- Total number of rights Equity shares applied for;
- On Application, Investors will have to pay an amount of ₹10.00/- (Rupees Ten Only) per Rights Share, as determined by the Board of Directors at its sole discretion;
- Details of the ASBA account such as a SCSB account, name, address, and branch of the relevant SCSB
- In case of the non-resident Eligible Equity shareholders making an application with an Indian address, details of NRE/FCNR/NRO account such as account number, name, address, and branch of the SCSB with which the account is maintained.
- Authorisation of the designated branch of the SCSB to block an account equivalent to the Application Money in the ASBA account
- Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB)
- All such Eligible Equity Shareholders are deemed to have accepted following:

'I We understand that neither the Rights Entitlement nor the Equity Shares have been, or will be, registered under the United States Securities Act of 1933, as amended (the 'US Securities Act') or any United States state securities laws, and may not be offered, sold, resold or otherwise transferred within the United States or to the territories or possessions thereof (the 'United States') except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act. I We understand the offering to which this application relates is not, and under no circumstances is to be construed as, an offering of any Equity Shares or Rights Entitlement for sale in the United States, or as a solicitation herein of an offer to buy any of the said Equity Shares or Rights Entitlement in the United States. Accordingly, I We understand that this application should not be forwarded to or transmitted in or to the United States at any time. If I understand that none of the Company, the Registrar, the Lead Managers or any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who we, the Registrar, the Lead Managers or any other person acting on behalf of the Company has reason to believe is in the United States, or if such person is outside India and the United States, such person is not a corporate shareholder, or is ineligible to participate in the Issue under the securities laws of their jurisdiction.

I We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorized or to any person to whom it is unlawful to make such offer, sale or invitation except under circumstances that will result in compliance with any applicable laws or regulations. I We satisfy, and each account for which we are acting satisfies, all suitability standards for investors in investments of the type specified for herein imposed by the jurisdiction of our residence.

I We acknowledge that we, the Lead Manager, its affiliates and others will rely upon the truth and accuracy of the foregoing representations and agreements.

**OVERSEAS SHAREHOLDERS -** The distribution of the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement letter, any other offering material and the issue of the Rights Entitlement and the Rights Equity Shares on a rights basis to persons in certain jurisdictions outside India are restricted by legal requirements prevailing in those jurisdictions. Our Company is making this issue of the Right Shares on a rights basis to the Equity Shareholders will dispatch the Letter of Offer/Abridged Letter of Offer to such Eligible Shareholders who have provided an Indian address to our Company. Those overseas Shareholders, who have not updated our records with their Indian address or the address of their duly authorized representative in India, prior to the date on which we propose to e-mail the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement letter, shall not be sent the Letter of Offer, the Abridged Letter of Offer, the Application Form and the Rights Entitlement letter.

**NO OFFER IN THE UNITED STATES -**  
 The Rights Entitlements and The Rights Equity Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act') and may not be offered or sold within the United States, except pursuant to an exemption from or in a transaction not subject to, the registration required of the U.S. Securities Act and Applicable State Securities Laws. Accordingly, the Rights Entitlements (including their credit) and the rights Equity Shares are only being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers, and the sales occur.

Neither our company nor any person acting on the behalf of our company, will accept a subscription or renunciation from any person or, agent of the any person, who appears to be, who our company, any other person acting on the behalf of the company, has Reasons to be believe is, in the United States when the buy order is made. No Application Forms should be postmarked in the United States, electronically transmitted from the United States or otherwise dispatched from United States and from any other jurisdiction where it would be illegal to make an offer of securities under the Letter of Offer. Our company is undertaking this issue on the Rights basis to the Eligible Equity Shares and will dispatch the letter of offer or Abridged letter of offer, and the Application Form, only to the Eligible Equity Shareholders who have provided an Indian address to our company. Any person who acquires Rights Entitlements or Rights Equity Shares will be deemed to have declared, warranted and agreed, by accepting the delivery of the letter of offer, that is not and that at the time of subscribing Rights Entitlements or Rights Equity Shares, it will not be, in the United States and authorized to acquire Rights Entitlements and Rights Equity Shares in compliance with the applicable laws and regulations.

Our Company, in consultation with the Lead Manager, reserves the right to treat as invalid any Application Form which (i) appears to our company and its agents to have been executed in, electronically submitted transmitted from, or dispatched from United States or other jurisdiction where the offer and sales of rights of Equity shares is not permitted under the law of the such jurisdiction; (ii) does not includes the relevant certifications set out in the Application Form, including to the effect that the person submitting and/or renouncing the Application Form is outside the United States and such person is Eligible to subscribe for the rights Equity shares under the applicable securities laws and complying with the laws of jurisdiction applicable to such person in connection with this issue or; (iii) where either a registered Indian address is not provided or where our company believes acceptances of such Application Form may infringe applicable legal or regulatory requirements, and our company shall not be bound to issue or allot any rights Equity shares in respect of any such Application Form.

**LAST DATE FOR APPLICATION:** The last date for submission of the duly filled in the Application Form or a plain paper Application is Thursday, May 30, 2024 i.e. issue closing date. Our board or the rights issue committee may extend such date for such period as it may determine from time to time, subject to the issue period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSB, uploaded with stock exchange and the application money is not blocked with the SCSB or if the Application Form is not accepted at the R-WAP or before the issue closing date or such date as may be extended by board or any committee thereof, the invitation to the offer contained in the letter of offer shall be deemed to be have been declined and our board or any committee thereof shall be at liberty to dispose of the Equity shares hereby offered, as set out in the section entitled - Basis of Allotment on the page no 167 of 'LOF'

**ALLOTMENT ONLY IN DEMATERIALIZED FORM:** The Allotment of Equity Shares pursuant to the Issue will only be made in Dematerialised Form. In accordance with the SEBI Rights Issue Circulars, (a) the Eligible Equity Shareholder, who hold Equity Shares in physical form as on Record Date; or (b) the Eligible Equity Shareholders, hold Equity Shares in physical form as on Record Date who have not furnished the details of their demat account to the Registrar or Company at least two Working Days prior to the issue Closing Date, desirous of subscribing to Rights Equity Shares may also apply in this issue during the Issue Period subject to certain conditions. Such resident Eligible Equity Shareholders must check the procedure for application by and credit of Rights Equity Shares of such Eligible Equity Shareholders in the sections entitled, 'Term of the Issue'. Making of an Application by Eligible Equity Shareholders holding Equity Shares in physical form and 'Terms of the issue' - Allotment Advice or Refund/Unblocking of ASBA Accounts beginning on page 168 of the Letter of Offer.

**INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGE ONLY IN DEMATERIALIZED FORM.**

**LISTING:** The Existing shares of the company are listed on BSE Limited ('BSE') or ('Stock Exchange'). The Company has received 'In-principle' approval from BSE for listing the rights Equity shares to be allotted pursuant to the issue letter bearing reference number LOD/RIGHT/DA/FP/50/2023-24 dated Monday, April 08, 2024. Our Company also will make application to BSE Limited to obtain trading approvals for the rights entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL/2/CIR/P/2020/13 dated January 22, 2021, for the purpose of the issue, the designated stock exchange is BSE.

**DISCLAIMER CLAUSE OF SEBI:** Submission of Letter of Offer to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the Letter of Offer. The investors are advised to refer to the full text of 'Disclaimer clause of SEBI' beginning on page 137 of the Letter of Offer.

**DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange):** It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. The investors are advised to refer to the letter of offer for the full text of disclaimer clause of BSE beginning on page 138 of Letter of Offer.

**ESCROW COLLECTION BANK, ALLOTMENT ACCOUNT BANKS, REFUND BANKER:** IndusInd Bank Limited

**DISPATCH AND AVAILABILITY OF ISSUE MATERIALS:** In accordance with the SEBI ICDR regulations the letter of offer, the Abridged letter of offer, the Application Form, the Right Entitlement letter and other issue material will be sent/ dispatched only to the Eligible Equity shareholders who have provided Indian address to our company and who are located in jurisdiction where offer and sale of the Rights Entitlement or Rights Equity shares is permitted under laws of such jurisdiction and does not result in and may not be construed as, a public offering in such jurisdiction. Further, Letter of offer will be sent / dispatched to the Eligible Equity shareholder who have provided Indian address to our company and who have made a request in this regard. In accordance with the above, the dispatched of the Abridged letter of offer, the Rights Entitlement letter along with the Application Form has been completed on 143 by Registrar to the Issue.

Eligible Equity Shareholder can also obtain of their respective rights entitlement from the website of the registrar i.e. [www.purvashare.com](http://www.purvashare.com); by entering their DP/ID and client ID or folio number (for Eligible Equity shareholder who hold Equity shares in physical form as on Record Date) and PAN. The link shall also be available on our company website [www.banasfinance.wordpress.com](http://www.banasfinance.wordpress.com)

Our company along with Lead Manager have taken and will continue to undertake all adequate steps to reach out the Eligible Equity shareholder who have provided their Indian address through means as may be considered feasible by our company and our company or the Lead Manager will not be liable for considered or choosing or not considering or choosing any specific means to reach out to the Eligible Equity shareholder.

Investors can access the letter of offer, Abridged letter of offer, and the Application Form (provided that the Eligible Equity shareholder is eligible to subscribe for the Rights Equity Shares under applicable laws) on the website of (i) our company [www.banasfinance.wordpress.com](http://www.banasfinance.wordpress.com), (ii) Registrar to an issue [www.purvashare.com](http://www.purvashare.com); (iii) stock exchange [www.bseindia.com](http://www.bseindia.com).

The investors can visit following links for the below mentioned purposes - a) Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the investors [www.purvashare.com](http://www.purvashare.com); b) Updating of an Indian address/Email address /phone -mobile number in the records maintained by registrar or our company [www.banasfinance.wordpress.com](http://www.banasfinance.wordpress.com); c) Updating of a demat account details by Eligible Equity Shareholders holding shares in physical form [www.banasfinance.wordpress.com](http://www.banasfinance.wordpress.com); d) Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Equity Shareholders; [newissue@purvashare.com](mailto:newissue@purvashare.com);

The LOF is also available on the website of SEBI at [www.sebi.gov.in](http://www.sebi.gov.in)

COMPANY DETAILS	REGISTRAR TO THE ISSUE
 <p><b>BANAS FINANCE LIMITED</b>                      E-109, Crystal Plaza, New Link Road, Andheri (West), Mumbai - 400053, Maharashtra, India;                      Contact Details: +91-9152096140                      Website: <a href="http://www.banasfinance.wordpress.com">www.banasfinance.wordpress.com</a>                      Email: <a href="mailto:banasfn@gmail.com">banasfn@gmail.com</a>                      Contact Person: Prajna Prakash Naik, Company Secretary and Compliance Officer;                      Corporate Identification Number: L65910MH1983PLC030142</p>	 <p><b>PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED</b>                      Unit No. 9, Ground Floor, Shiv Shakti Industrial Estate, J. R. Boricha Marg, Lower Parel (East), Mumbai - 400011, Maharashtra, India;                      Contact Number: +22-49614132/022-35220056                      E-mail ID / Investor grievance e-mail: <a href="mailto:newissue@purvashare.com">newissue@purvashare.com</a>;                      Website: <a href="http://www.purvashare.com">www.purvashare.com</a>;                      Validity of Registration: Permanent.</p>

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre-issue or post issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs giving full details such as name, address of the Applicant, contact number(s), e-mail address of the Sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip.

For, Banas Finance Limited  
 On behalf of the Board of Directors  
 Sd/-  
 Girraj Kishor Agrawal  
 Executive Director

Place: Mumbai  
 Date: Thursday, May 09, 2024

